21 Novembre 2026

Psicologia Punto One | Psicologia e Psicologi nel Web

Menu

Menu

SCHEDA SCIENTIFICA2026Altra ricerca

Fear of Recurrence and Medication Adherence in Pediatric Leukaemia Survivors in Low-Resource Settings.

Saha S, Mohammed AF, Nagula D, Chakrabarti P, Vunyorohwashe M, Anwar S, Tripathi KM, Khan SH, Maqbool KW, Shazia K

Juntendo medical journal · 2026

Abstract originale

OBJECTIVES: Childhood leukaemia patients who survived their treatment often experience Fear of Cancer Recurrence (FCR), which can affect Medication Adherence (MA), particularly in low-resource environments. This paper explored the relationship between FCR and adherence among pediatric survivors. MATERIALS AND METHODS: A cross-sectional study was conducted in tertiary care pediatric oncology clinics in low-resource settings, involving 444 children diagnosed with Acute Lymphoblastic Leukaemia (ALL) or Acute Myeloid Leukaemia (AML). The FCR was assessed using the validated Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF), and adherence was assessed using the validated Medication Adherence Rating Scale (MARS-10). The statistical tests were correlation test, independent t-tests, one-way ANOVA, and multiple linear regression. RESULTS: The average FCRI-SF score was 27.0 +/- 2.6, and the average MARS-10 score was 15.1 +/-1.1. Medication adherence was significantly negatively associated with fear of cancer recurrence (r = -0.210, p < 0.001). Women had higher FCRI-SF (27.4 ± 2.9) than men (26.5 ± 2.4), and lower MARS-10 scores (14.8 ± 1.1 vs. 15.4 ± 1.0). The highest FCR (27.8 ± 2.4) and the lowest adherence (14.7 ± 1.0) were found in adolescents (15-17 years). Regression analysis revealed that FCR (B = -0.15, p = 0.001), female gender (B = -0.40, p = 0.001), treatment phase (B = -0.09, p = 0.003), and missed chemotherapy cycles (B = -0.07, p = 0.001) were significant predictors of poor adherence. CONCLUSION: FCR is a significant psychological risk factor of medication adherence in survivors of paediatric leukaemia. Psychosocial support and follow-up strengthening can be used to decrease non-adherence and treatment abandonment.

Parole chiave

fear of cancer recurrencemedication adherencepediatric leukaemiasurvivorshipMedication AdherenceFear Of Cancer RecurrencePediatric Leukaemia
Leggi il testo integrale originale

Testo estratto dalla pubblicazione: sono esclusi immagini, media, supplementi e parti soggette a diritti distinti.

Fear of Recurrence and Medication Adherence in Pediatric Leukaemia Survivors in Low-Resource Settings

Objectives

Childhood leukaemia patients who survived their treatment often experience Fear of Cancer Recurrence (FCR), which can affect Medication Adherence (MA), particularly in low-resource environments. This paper explored the relationship between FCR and adherence among pediatric survivors.

Materials and Methods

A cross-sectional study was conducted in tertiary care pediatric oncology clinics in low-resource settings, involving 444 children diagnosed with Acute Lymphoblastic Leukaemia (ALL) or Acute Myeloid Leukaemia (AML). The FCR was assessed using the validated Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF), and adherence was assessed using the validated Medication Adherence Rating Scale (MARS-10). The statistical tests were correlation test, independent t-tests, one-way ANOVA, and multiple linear regression.

Results

The average FCRI-SF score was 27.0 +/- 2.6, and the average MARS-10 score was 15.1 +/-1.1. Medication adherence was significantly negatively associated with fear of cancer recurrence (r = -0.210, p < 0.001). Women had higher FCRI-SF (27.4 ± 2.9) than men (26.5 ± 2.4), and lower MARS-10 scores (14.8 ± 1.1 vs. 15.4 ± 1.0). The highest FCR (27.8 ± 2.4) and the lowest adherence (14.7 ± 1.0) were found in adolescents (15-17 years). Regression analysis revealed that FCR (B = -0.15, p = 0.001), female gender (B = -0.40, p = 0.001), treatment phase (B = -0.09, p = 0.003), and missed chemotherapy cycles (B = -0.07, p = 0.001) were significant predictors of poor adherence.

Conclusion

FCR is a significant psychological risk factor of medication adherence in survivors of paediatric leukaemia. Psychosocial support and follow-up strengthening can be used to decrease non-adherence and treatment abandonment.

Introduction

The most common cancer type in children is childhood leukaemia, and its onset is due to the abnormal growth of white blood cells in the bone marrow, which interferes with normal haematopoiesis1). Childhood cancers such as leukaemia remain highly morbid and lethal and have few new treatments because of their rarity and biological diversity. In 2021, the reported childhood leukaemia cases were estimated worldwide to be 58,785, and the most significant number of cases and deaths were reported in Low Socio-Demographic Index (SDI) regions, with the highest number of cases affecting infants and boys2, 3).

Acute leukaemias of childhood, particularly precursor B-cell Acute Lymphoblastic Leukaemia (ALL), tend to have an aetiological basis during the uterine period, with subsequent influences during the postnatal period, including infections and immune-associated genetic variations, which influence the disease4). L-asparaginase is a fundamental treatment for pediatric ALL. Yet, immunogenicity, allergic reactions, and drug resistance limit its use, fueling the emergence of new variants and the development of individualised treatment approaches5).

Survivorship also introduces a new dimension of concern, such as fear of cancer recurrence (FCR), that afflicts a significant percentage of childhood cancer survivors; about 43% of childhood cancer survivors report at least once, and 21% report persistently. Higher depressive symptoms and younger age of diagnosis correlate with higher FCR, which in most cases accompany long-term symptoms like pain and fatigue6, 7).

Treatment abandonment, which entails the inability to finish therapy to control the disease, is a leading factor in treatment failure among children with cancer in low and middle-income countries8). Medication non-adherence exists on a continuum, with treatment abandonment representing its most severe form. Minor lapses, such as missed appointments or incomplete follow-up, may progressively lead to treatment abandonment, particularly in low- resource pediatric oncology settings9, 10). About 25% of children who have ALL withdraw therapy, significant ones being the costs of treatment, the belief in the incurability of the condition, problems in transportation, and the fear of adverse effects of treatment11, 12).

In low-resource settings, limited access to follow- up care, psychosocial services, and health education may amplify fear of recurrence. These systemic gaps can exacerbate anxiety-driven non-adherence, increasing the risk of treatment interruption or abandonment9). The interaction between fear of recurrence and treatment abandonment holds essential information to make effective survivorship care strategies. These factors can significantly impair the medical prognosis and mental health in resource-limited settings where psychosocial support is frequently low. Thus, the current research seeks to investigate the relationship between fear of recurrence and treatment abandonment in low- resource settings among pediatric patients who have survived leukaemia to establish the crucial psychosocial and systemic predictors that can be used in future interventions and policy formulation.

Objectives

The main aim of the research is to investigate the rates and severity of FCR among survivors of childhood leukaemia in low-resource countries and to examine their correlation with treatment adherence. The study also seeks to determine the most important demographic, clinical, and psychosocial variables that may affect fear of recurrence and compliance with follow-up care. With knowledge of these determinants, the study aims to inform how survivors and their families face difficulties and where interventions, support programs, and policy modifications can be applied to curb treatment abandonment and improve overall survivorship in resource-constrained settings.

Materials and Methods

Ethical considerations

The institutional ethics review board of Scarborough General Hospital, Scarborough, United Kingdom (Approval No.: SGH-REC-2024-017) approved the study. Informed consent was obtained in written form from parents or legal guardians, and children aged seven or older provided assent. The involvement was voluntary, and confidentiality was ensured. Caregivers and children were assured that refusal or disengagement from the survey would not affect their ongoing medical care.

Study approach and contextual setting

The cross-sectional study was conducted in tertiary care hospitals and pediatric oncology clinics in low-resource urban and semi-urban regions. The study sought to examine the relationship that exists between FCR and treatment abandonment among survivors of pediatric leukaemia.

Study population and sampling

The patient population consisted of children aged between 5 and 18 years who had attained remission after being diagnosed with acute lymphoblastic or acute myeloid leukaemia. Only survivors who would not have a profound cognitive deficit or comorbidity that would have jeopardised participation were taken into consideration. A total of 444 participants, together with their primary caregivers, were recruited via convenience sampling to obtain a representative sample of survivors receiving follow-up care in low-resource settings. Convenience sampling was employed due to the absence of centralised survivorship registries, logistical constraints, and the need to maximise participant inclusion in low-resource pediatric oncology settings.

Data collection instruments

Data were collected using three structured tools:

Demographic questionnaire

A structured questionnaire was created to document age, gender, leukaemia type, treatment history, length of remission, family socioeconomic status, and distance.

Medication adherence rating scale (MARS)

The MARS was developed by Thompson et al. (2000) to measure treatment adherence and consists of 10 items that assess medication adherence behaviours and attitudes. The items are rated using a dichotomy (Yes = 1, No = 0), and the overall score indicates better adherence. In children under 7 years of age, the primary caregiver would complete the MARS on behalf of the child; those 7 years or older would complete it themselves13).

Fear of cancer recurrence inventory-short form (FCRI-SF)

The FCRI-SF, developed by Simard and Savard in 2009, was used to measure FCR. This 9-item scale measures the severity of worry about cancer experienced in the previous month using a 5-point Likert scale (0 = never, 4 = almost always). The total score ranges from 0 to 36, with higher scores indicating greater fear of recurrence. In younger children, the caregiver provided the information on behalf of the child, but older children provided it themselves14).

Procedure

Data were collected through face-to-face interviews and from medical records. Parents or guardians provided informed consent, and children aged seven or older provided assent. For younger survivors, caregiver-reported responses were collected, as caregivers are primarily responsible for treatment supervision. Caregiver and self-reports were analysed together to reflect real-world adherence behaviours. Psychological support was provided to participants if they felt distressed when discussing recurrence or adherence.

Scoring and interpretation

MARS: Total scores were summed; higher scores indicate greater adherence.

FCRI-SF: Scores were added and classified as low, moderate and high fear of recurrence according to recommended cut-offs.

The descriptive and subgroup analyses were conducted based on demographic variables.

Data analysis

Data analysis was conducted in SPSS version 26. Descriptive statistics summarized demographic characteristics, fear of recurrence, and adherence scores. Pearson correlation was used to examine relationships between continuous variables (FCRI- SF and MARS-10). Independent samples t-tests and one-way ANOVA were used to compare groups, while multiple linear regression identified predictors of medication adherence. The level of statistical significance was set at p < 0.05.

Results

Summary of participant demographic characteristics

Table 1 summarises the demographics of 444 children with leukaemia. The majority of the respondents were teenagers aged 15-17 years (297, 66.9%) and male (257, 57.9%). The children mostly attended higher secondary school or college (115, 25.9% or high school (Grades 910; 106, 23.9%), and their living conditions were in urban (195, 43.9%) or rural areas (148, 33.3%). The number of acute myeloid leukaemia (AML, 268, 60.4%), acute lymphoblastic leukaemia (ALL, 176, 39.6%), and 153 (34.5%) were diagnosed within six months. The distribution of treatment stages was quite balanced, but the response to chemotherapy was not homogeneous, and the vast majority of children reported mild to severe side effects.

Table 1Demographic characteristics of participants (N = 444)

Variable f (N) % Variable f (N) %

Child's age 25-34 years 150 33.8

5-7 years 8 1.8 35-44 years 100 22.5

8-11 years 41 9.2 45-54 years 75 16.9

12-14 years 98 22.1 55 years or above 59 13.3

15-17 years 297 66.9 Parent/Caregiver educational level

Child’s gender No formal education 108 24.3

Male 257 57.9 Primary (Grades 1-5) 128 28.8

Female 187 42.1 Middle (Grades 6-8) 73 16.4

Child’s educational level High school (Grades 9-10) 49 11.0

Not attending school 63 14.2 Higher secondary/college 54 12.2

Primary (Grades 1-5) 90 20.3 University/professional 32 7.2

Middle (Grades 6-8) 70 15.8 Leukaemia type

High school (Grades 9-10) 106 23.9 ALL (Acute lymphoblastic leukaemia) 176 39.6

Higher secondary/college 115 25.9 AML (Acute myeloid leukaemia) 268 60.4

Residence place Time since diagnosis

Urban 195 43.9 < 6 months 153 34.5

Semi-urban 101 22.7 6-12 months 94 21.2

Rural 148 33.3 1-2 years 79 17.8

Distance to treatment center > 2 years 118 26.6

< 5 km 99 22.3 Current treatment phase

5-10 km 128 28.8 Induction 121 27.3

11-25 km 99 22.3 Consolidation/Intensification 120 27.0

> 25 km 118 26.6 Maintenance 96 21.6

Travel time to hospital Completed 107 24.1

< 30 minutes 137 30.9 Number of chemotherapy cycles missed

30-60 minutes 141 31.8 None 191 43.0

1-2 hours 85 19.1 1 therapy 81 18.2

>2 hours 81 18.2 2 therapies 64 14.4

Parent/Caregiver relationship to child > 2 therapies 108 24.3

Mother 200 45.0 Experience of treatment side effects

Father 180 40.5 None 32 7.2

Other relative/guardian 64 14.4 Mild 158 35.6

Parent/Caregiver age Moderate 110 24.8

< 25 years 60 13.5 Severe 144 32.4

Note. f = frequency, % = percentage; Values are presented as N (%), N = 444; No statistical comparisons were performed for demographic variables in this table.

Correlation between fear of cancer recurrence and medication adherence

Table 2 shows a significant negative correlation between fear of cancer recurrence (FCRI-SF) and medication adherence (MARS-10) (r = -0.210, t = -4.52, df = 442, p < 0.001). This indicates that higher fear of recurrence was associated with lower medication adherence. In this study, non-adherence is used as a proxy for treatment abandonment in pediatric leukaemia survivors.

Table 2Association between fear of cancer recurrence (FCRI-SF) and medication adherence (MARS-10) (N = 444)

Variables r t(df) p

Total fear of cancer recurrence inventory-short form (FCRI-SF) - - -

Total medication adherence rating scale (MARS) -0.210 -4.52 (442) <0.001**

Note. Values represent Pearson correlation coefficients (r) between continuous variables; N = 444; p < 0.001 (2-tailed) was considered statistically significant and is denoted with double asterisks (**).

Gender-based differences in fear of cancer recurrence and medication adherence

Table 3 reveals that there was a significant gender difference in both fear of recurrence of cancer and medication adherence among the 444 respondents. Females reported slightly higher fear of cancer recurrence (M = 27.4 ± 2.9) than males (M = 26.5 ± 2.4), which was statistically significant (t = -3.10, p = 0.002, Cohen’s d = 0.38). Conversely, males showed higher medication adherence (M = 15.4 ± 1.0) than females (M = 14.8 ± 1.1; t = 4.20, p < 0.001, Cohen’s d = 0.50). These results indicate a small-to-moderate gender difference in both FCR and adherence.

Table 3Gender differences in fear of cancer recurrence (FCRI-SF) and medication adherence (MARS) (N = 444)

Variables Male (N=257; 57.9%);(M ± SD) Female (N=187; 42.1%);(M ± SD) t p 95% CI Cohen's d

LL UL

Total fear of cancer recurrence inventory-short form (FCRI-SF) 26.50 ± 2.40 27.40 ± 2.90 -3.10 0.002** -1.46 -0.34 0.38

Total medication adherence rating scale (MARS) 15.40 ± 1.00 14.80 ± 1.10 4.20 < 0.001** 0.31 0.82 0.50

Note. Values are presented as Mean ± Standard Deviation; Independent samples t-tests were conducted to compare participants of both male and female groups; Group sizes are shown as N (%); Reported statistics include p-values, t-values, 95% Confidence Intervals (CI), and effect sizes (Cohen’s d); A p-value < 0.001 was considered statistically significant, N = 444.

Visual comparison of gender differences in FCRI-SF and MARS scores

Figure 1 shows gender variations in FCRI-SF and MARS scores among the 444 participants. Females reported slightly higher fear of cancer recurrence (FCRI-SF) than males, while males demonstrated higher medication adherence (MARS). These differences were statistically significant, indicating a small-to-moderate effect of gender on both FCR and adherence.

Age-related differences in fear of cancer recurrence and medication adherence

Age-related differences in FCR and medication adherence are presented in Table 4. FCR increased with age (F(3, 440) = 11.02, p < 0.001, η2 = 0.070), with adolescents (15-17 years) reporting the highest fear. Medication adherence declined slightly with age (F(3, 440) = 3.90, p = 0.009, η2 = 0.026), suggesting a minimal age effect. These findings indicate that older children and adolescents experience greater fear of recurrence and slightly lower adherence.

Table 4Age differences in fear of cancer recurrence (FCRI-SF) and medication adherence (MARS-10) among children and adolescents (N = 444)

Variables 5-7 years (N = 8; 1.8);(M ± SD) 8-11 years (N = 41; 9.2);(M ± SD) 12-14 years (N = 98; 22.1);(M ± SD) 15-17 years (N = 297; 266.9);(M ± SD) F(3,440) p η2

Total fear of cancer recurrence inventory-short form (FCRI-SF) 25.00 ± 2.50 26.20 ± 2.60 27.10 ± 2.70 27.80 ± 2.40 11.02 <0.001*** 0.070

Total medication adherence rating scale (MARS) 15.30 ± 0.90 15.10 ± 1.00 14.90 ± 1.05 14.70 ± 1.00 3.90 0.009** 0.026

Note. Data are presented as Mean ± Standard Deviation (M ± SD); Group sizes are shown as N (%); One-way ANOVA was conducted to examine the effect; All comparisons were significant at p < 0.01, < 0.001; η2 represents partial eta-squared effect size.

Predictors of medication adherence based on psychological, demographic, and clinical factors

Table 5 presents the results of multiple regression-based prediction of medication adherence among children with leukaemia. Multiple linear regression (Table 5) showed that higher FCRI-SF scores significantly predicted lower medication adherence (B = -0.15, β = -0.35, t = -5.00, p < 0.001). Older age predicted greater adherence (B = 0.10, β = 0.20, t = 4.00, p < 0.001), while female gender predicted lower adherence (B = -0.40, β = -0.18, t = -3.33, p = 0.001). Clinical variables also influenced adherence: leukaemia type (B = 0.22, β = 0.12, p = 0.006), current treatment phase (B = -0.09, β = -0.12, p = 0.003), and number of missed chemotherapy cycles (B = -0.07, β = -0.11, p < 0.001) were significant predictors. Overall, psychological, demographic, and treatment-related factors contribute to medication adherence among pediatric leukaemia survivors.

Table 5Multiple regression predicting medication adherence (MARS-10) from fear of cancer recurrence, age, gender, and clinical variables (N = 444)

Predictor B SE β t p 95% CI lower 95% CI upper

(Constant) 13.50 0.50 - 27.00 < 0.001*** 12.52 14.48

Total FCRI-SF -0.15 0.03 -0.35 -5.00 < 0.001*** -0.21 -0.09

Child age (years) 0.10 0.03 0.20 4.00 < 0.001*** 0.05 0.15

Child gender (female) -0.40 0.12 -0.18 -3.33 0.001** -0.64 -0.16

Leukemia type 0.22 0.08 0.12 2.75 0.006** 0.06 0.38

Current treatment phase -0.09 0.03 -0.12 -3.00 0.003** -0.15 -0.03

Number of chemotherapy cycles missed -0.07 0.02 -0.11 -3.50 < 0.001*** -0.11 -0.03

Note. Multiple linear regression was conducted to identify predictors of Medication Adherence (MARS-10) Scores; Values include unstandardized coefficients (B), 95% confidence intervals (CI), standard error (SE), standardised beta coefficients (β), and p-values; **= p < 0.01, ***= p < 0.001 was considered statistically significant, N = 444.

Discussion

In the current research, the FCR was a significant predictor of poor medication adherence among patients with leukaemia, and this meant that the anxiety related to the disease returning may decrease adherence to medications. This is in line with the earlier studies, which reported fear of recurrence to be strongly correlated with medication beliefs and illness perceptions, which indicate that the psychological aspects can affect the adherence behaviour among all cancer populations15).

The observed gender differences suggest that female survivors may experience greater emotional vulnerability, which could partially explain lower adherence behaviors, and the effect was slight-to-moderate, consistent with previous findings of slight but consistent gender differences in FCR16). Consequently, medication adherence was higher in male participants compared to female participants, which agrees with the literature that female cancer survivors tend to report cost-related or overall non- adherence17).

Age was also correlated with FCR and adherence. The FCR was highest among adolescents and lowest among the youngest children (5-7 years), which aligns with a developmental approach, in which older children tend to be more aware of potential health risks18). In line with this, compliance was minimally age-dependent, with adolescents less compliant than younger children, suggesting decreased parental supervision and increased autonomy19).

Greater FCR was a predictor of worse medication adherence, with females showing slightly lower adherence, and age affecting adherence patterns, consistent with prior research15, 17, 19). Clinical factors also influenced adherence patterns. The type of leukaemia was a significant predictor of adherence, and some subtypes showed slightly higher MARS- 10 scores, as previously reported20). The level of medication adherence also decreased in the latter, more intensive stages of treatment, probably because of the increased weight of home-based maintenance treatment and issues with caregivers21). Lastly, lower adherence was linked to absenteeism from chemotherapy sessions, highlighting the clinical significance of continuous oral maintenance therapy in pediatric ALL22).

Together, these findings underscore the synergies among psychological, demographic, and clinical factors in medication compliance among children with leukaemia. These findings highlight the importance of integrating routine screening for fear of recurrence into survivorship care, particularly for adolescents and female survivors. Targeted psychosocial interventions may help mitigate anxiety-driven non-adherence.

Limitations of our study and future recommendations

This research has several limitations that must be taken into account when analysing the outcomes. First, the cross-sectional design does not allow for causal inference regarding the relationship between fear of recurrence and adherence. Second, self- report scales, particularly when an adult completes them on behalf of young children, can be vulnerable to response and social desirability bias. Third, convenience sampling of hospitals limits the generalizability of the results to all low-resource areas. Lastly, some contextual variables, including financial burden, cultural attitudes toward cancer and access to transportation, were also not examined but could be significant contributors to adherence and psychological distress. Additionally, medication adherence was self-reported, which may introduce recall or social desirability bias. Finally, the study did not include a qualitative exploration of psychosocial factors, limiting the understanding of underlying barriers to adherence.

Future studies ought to use longitudinal designs to monitor fear of recurrence and adherence patterns throughout and after treatment. Psychosocial intervention, including counselling, family-based support programs and structured survivorship education, needs to be considered culturally adapted to decrease FCR and enhance adherence. Furthermore, health systems in low-resource countries should consider approaches such as engaging community health workers, providing telemedicine follow-ups, and implementing financial or logistical support interventions to reduce treatment abandonment. Additional information about the family's experience and barriers to regular care could also be obtained through qualitative research.

Conclusion

Overall, it is concluded that FCR is associated with poor medication adherence among low-resource setting pediatric survivors of leukaemia. The research demonstrates the interplay among psychological, demographic, and clinical factors in adherence behaviour, as well as the importance of integrative survivorship care. The treatment of FCR in childhood leukaemia survivors by identifying it early, supporting it using psychosocial means, and improving the system can potentially decrease the rate of treatment abandonment and improve overall long-term survival. At a policy level, strengthening survivorship programs with integrated psychosocial support and adherence monitoring is essential to reduce treatment abandonment in low-resource pediatric oncology settings.

Data availability

The datasets generated and analysed during the current study are available from the corresponding author on reasonable request.

Author contributions

SS and AFM conceived and designed the study and supervised the overall project. DN and PC contributed to conceptual support, data interpretation, and critical revision of the manuscript. MV and SA were responsible for data analysis, manuscript preparation, and final approval. KMT and SHK contributed to the literature review and referencing. KWM assisted with data validation and statistical review. KS coordinated formatting, proofreading, and preparation of tables and figures. All authors read and approved the final manuscript.

Conflicts of interest statement

The authors declare that there are no conflicts of interest.

References

1)Ruiz J , Mathews C , Friehling E : What is childhood leukemia? JAMA , 2024 ; 331 : 808 .10.1001/jama.2023.24648 38334982

2)Greaves M , Cazzaniga V , Ford A : Can we prevent childhood leukaemia? Leukemia , 2021 ; 35 : 1258 -1264 .10.1038/s41375-021-01211-7 PMC8102184 33833382

3)Liu W , Fang J , Zhu M , Zhou J , Yuan C : Global, regional, and national burden of childhood leukemia from 1990 to 2021. BMC Pediatr , 2025 ; 25 : 571 .10.1186/s12887-025-05847-7 PMC12297649 40713505

4)Eden T : Aetiology of childhood leukaemia. Cancer Treat Rev , 2010 ; 36 : 286 -297 .10.1016/j.ctrv.2010.02.004 20223594

5)Zhou R , Liang T , Li T , Huang J , Chen C : Possible mechanism of metabolic and drug resistance with L-asparaginase therapy in childhood leukaemia. Front Oncol , 2023 ; 13 : 1070069.10.3389/fonc.2023.1070069 PMC9929349 36816964

6)Wroot H , Afzal AR , Forbes C , et al: Fear of cancer recurrence among survivors of childhood cancer. Psychooncology , 2020 ; 29 : 1132 -1140 .10.1002/pon.5387 32281171

7)Kelada L , Wakefield CE , Heathcote LC , et al: Perceived cancer-related pain and fatigue, information needs, and fear of cancer recurrence among adult survivors of childhood cancer. Patient Educ Couns , 2019 ; 102 : 2270 -2278 .10.1016/j.pec.2019.06.022 31257099

8)Weaver MS , Arora RS , Howard SC , et al: A practical approach to reporting treatment abandonment in pediatric chronic conditions. Pediatr Blood Cancer , 2015 ; 62 : 565 -570 .10.1002/pbc.25403 25586157

9)Salaverria C , Rossell N , Hernandez A , et al: Interventions targeting absences increase adherence and reduce abandonment of childhood cancer treatment in El Salvador. Pediatr Blood Cancer , 2015 ; 62 : 1609 -1615 .10.1002/pbc.25557 PMC4418179 25925227

10)Weaver MS , Arora RS , Howard SC , et al: A practical approach to reporting treatment abandonment in pediatric chronic conditions. Pediatr Blood Cancer , 2015 ; 62 : 565 -570 .10.1002/pbc.25403 25586157

11)Sitaresmi MN , Mostert S , Schook RM , Sutaryo, Veerman AJP: Treatment refusal and abandonment in childhood acute lymphoblastic leukemia in Indonesia: an analysis of causes and consequences. Psychooncology , 2010 ; 19 : 361 -367 .10.1002/pon.1578 19434599

12)Wang Y , Jin R , Xu J , Zhang Z : A report about treatment refusal and abandonment in children with acute lymphoblastic leukemia in China, 1997-2007. Leuk Res , 2011 ; 35 : 1628 -1631 .10.1016/j.leukres.2011.07.004 21802727

13)Thompson K , Kulkarni J , Sergejew AA : Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res , 2000 ; 42 : 241 -247 .10.1016/s0920-9964(99)00130-9 10785582

14)Simard S , Savard J : Fear of Cancer Recurrence Inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. Support Care Cancer , 2009 ; 17 : 241 -251 .10.1007/s00520-008-0444-y 18414902

15)Corter AL , Findlay M , Broom R , Porter D , Petrie KJ : Beliefs about medicine and illness are associated with fear of cancer recurrence in women taking adjuvant endocrine therapy for breast cancer. Br J Health Psychol , 2013 ; 18 : 168 -181 .10.1111/bjhp.12003 23134580

16)Pang C , Humphris G : The relationship between fears of cancer recurrence and patient gender: a systematic review and meta-analysis. Front Psychol, 2021 ; 12 : 640866.10.3389/fpsyg.2021.640866 PMC7937637 33692731

17)Lee M , Khan MM : Gender differences in cost-related medication non-adherence among cancer survivors. J Cancer Surviv , 2016 ; 10 : 384 -393 .10.1007/s11764-015-0484-5 26350680

18)Tutelman PR , Heathcote LC : Fear of cancer recurrence in childhood cancer survivors: a developmental perspective from infancy to young adulthood. Psychooncology , 2020 .10.1002/pon.5576 33068463

19)Farberman D , Mastera M , Valente P , et al: Adherence to oral antineoplastic agents in pediatric oncology: a multicenter study. Arch Argent Pediatr , 2021 ; 119 : 44 -50 .10.5546/aap.2021.eng.44 33458980

20)Rohan JM , Drotar D , Alderfer M , et al: Electronic monitoring of medication adherence in early maintenance phase treatment for pediatric leukemia and lymphoma: identifying patterns of nonadherence. J Pediatr Psychol , 2015 ; 40 : 75 -84 .10.1093/jpepsy/jst093 PMC4288299 24365698

21)França FA , Catarina A , Tessmann L , et al: Barriers to medication adherence by caregivers of children with leukemia: an observational study. Rev Paul Pediatr , 2024 ; 42 : e2022214.

22)Zeng XL , Heneghan MB , Badawy SM : Adherence to oral chemotherapy in acute lymphoblastic leukemia during maintenance therapy in children, adolescents, and young adults: a systematic review. Curr Oncol , 2023 ; 30 : 720 -748 .10.3390/curroncol30010056 PMC9858168 36661705

Come citare questo studio

Saha S, Mohammed AF, Nagula D, Chakrabarti P, Vunyorohwashe M, Anwar S, Tripathi KM, Khan SH, Maqbool KW, Shazia K. (2026). Fear of Recurrence and Medication Adherence in Pediatric Leukaemia Survivors in Low-Resource Settings.. Juntendo medical journal

Consulta la pubblicazione originale ↗